Skip to main content
Top
Published in: Neuroscience Bulletin 5/2017

01-10-2017 | Research Highlight

Milestones of Parkinson’s Disease Research: 200 Years of History and Beyond

Authors: Song Li, Weidong Le

Published in: Neuroscience Bulletin | Issue 5/2017

Login to get access

Excerpt

Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Since its first description as a neurological disorder by James Parkinson (1755–1824) in 1817, many important discoveries have been made during this 200 years of PD research history. These milestones have revealed many aspects of PD, including clinical and pathological characteristics, anatomy and neurochemistry, environmental and genetic factors, hypothesis of peripheral to central spread, and advances in diagnostic technology and therapeutic approaches. All these achievements have shed light on the pathophysiological process of PD and have further explored the comprehensive management of this disease. However, this journey to conquer PD is still far from being accomplished. Early and precise diagnosis strategies, together with disease-modifying therapy, are urgently needed. To this end, it is necessary to recall these milestones in PD research history and appreciate their lasting impact on current and future PD research. In a historical review article published recently in Nature Reviews Neuroscience, Dr. Serge Przedborski recounted the fascinating 200-year journey of PD [1]. To better highlight the historical milestones of PD research, here, we have extracted important discoveries from Dr. Przedborski’s timely review paper. In addition, we also provide important supplementary information to emphasize the significant contributions of research findings from East and West before James Parkinson. …
Literature
1.
go back to reference Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017, 18: 251–259.CrossRefPubMed Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017, 18: 251–259.CrossRefPubMed
3.
go back to reference Sider D, McVaugh M. Galen on tremor, palpitation, spasm, and rigor. Trans Stud Coll Physicians Phila 1979, 1: 183–210.PubMed Sider D, McVaugh M. Galen on tremor, palpitation, spasm, and rigor. Trans Stud Coll Physicians Phila 1979, 1: 183–210.PubMed
4.
go back to reference Calne DB, Dubini A, Stern G. Did Leonardo describe Parkinson’s disease? New Engl J Med 1989, 320: 594.PubMed Calne DB, Dubini A, Stern G. Did Leonardo describe Parkinson’s disease? New Engl J Med 1989, 320: 594.PubMed
5.
go back to reference Bereczki D. The description of all four cardinal signs of Parkinson’s disease in a Hungarian medical text published in 1690. Parkinsonism Relat Disord 2010, 16: 290–293.CrossRefPubMed Bereczki D. The description of all four cardinal signs of Parkinson’s disease in a Hungarian medical text published in 1690. Parkinsonism Relat Disord 2010, 16: 290–293.CrossRefPubMed
6.
go back to reference Zhang Z, Dong Z, Roman GC. Early descriptions of Parkinson disease in Ancient China. Arch Neurol 2006, 63: 782–784.CrossRefPubMed Zhang Z, Dong Z, Roman GC. Early descriptions of Parkinson disease in Ancient China. Arch Neurol 2006, 63: 782–784.CrossRefPubMed
7.
go back to reference Brissaud É. Leçons sur les maladies nerveuses (Deuxième série, Hôpital Saint-Antoine) recueillies et publiées par Henry Meige. Masson, Paris, 1899. Brissaud É. Leçons sur les maladies nerveuses (Deuxième série, Hôpital Saint-Antoine) recueillies et publiées par Henry Meige. Masson, Paris, 1899.
8.
go back to reference Forster E, Lewy FH. Paralysis agitans. I. Pathologische Anatomie (von F.H. Lewy). In: Lewandowsky M, Abelsdorff G (Eds.), Handbuch der Neurologie, 3rd Edn. Springer, Berlin 1912: 920–933. Forster E, Lewy FH. Paralysis agitans. I. Pathologische Anatomie (von F.H. Lewy). In: Lewandowsky M, Abelsdorff G (Eds.), Handbuch der Neurologie, 3rd Edn. Springer, Berlin 1912: 920–933.
9.
go back to reference Tretiakoff C, Contribution à l’étude de l’anatomie pathologique du locus niger de Sommering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Thèse méd. Paris, No. 293, 1919. Tretiakoff C, Contribution à l’étude de l’anatomie pathologique du locus niger de Sommering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Thèse méd. Paris, No. 293, 1919.
10.
go back to reference Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960, 38: 1236–1239.CrossRefPubMed Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960, 38: 1236–1239.CrossRefPubMed
11.
go back to reference Barbeau A. Biochemistry of Parkinson’s disease. In: Proceedings of the seventh international congress of neurology, Rome, Sept, Societa Grafica Romana, Rome, 1961, 2: 925. Barbeau A. Biochemistry of Parkinson’s disease. In: Proceedings of the seventh international congress of neurology, Rome, Sept, Societa Grafica Romana, Rome, 1961, 2: 925.
12.
go back to reference Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970, 282: 31–33.CrossRefPubMed Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970, 282: 31–33.CrossRefPubMed
14.
go back to reference Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson’s disease: problems and possibilities. Prog Brain Res 2010, 184: 265–294.CrossRefPubMed Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson’s disease: problems and possibilities. Prog Brain Res 2010, 184: 265–294.CrossRefPubMed
15.
go back to reference Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol 2015, 11: 492–503.CrossRefPubMed Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol 2015, 11: 492–503.CrossRefPubMed
16.
go back to reference Backlund EO, Granberg PO, Hamberger B, Knutsson E, Mårtensson A, Sedvall G, Seiger A, Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985, 62: 169–173.PubMed Backlund EO, Granberg PO, Hamberger B, Knutsson E, Mårtensson A, Sedvall G, Seiger A, Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985, 62: 169–173.PubMed
17.
go back to reference Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001, 344: 710–719.CrossRefPubMed Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001, 344: 710–719.CrossRefPubMed
18.
go back to reference Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60: 69–73.CrossRefPubMed Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60: 69–73.CrossRefPubMed
19.
go back to reference Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987, 50: 344–346.PubMed Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987, 50: 344–346.PubMed
20.
go back to reference Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995, 345: 91–95.CrossRefPubMed Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995, 345: 91–95.CrossRefPubMed
21.
go back to reference Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease. Neurology 1998, 51: 850–855.CrossRefPubMed Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease. Neurology 1998, 51: 850–855.CrossRefPubMed
22.
23.
go back to reference Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24: 197–211.CrossRefPubMed Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24: 197–211.CrossRefPubMed
24.
go back to reference Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219: 979–980.CrossRefPubMed Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219: 979–980.CrossRefPubMed
25.
go back to reference Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine. Proc Natl Acad Sci U S A 1983, 80: 4546–4550.CrossRefPubMedPubMedCentral Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine. Proc Natl Acad Sci U S A 1983, 80: 4546–4550.CrossRefPubMedPubMedCentral
26.
go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839–840.CrossRefPubMed Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839–840.CrossRefPubMed
27.
go back to reference Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276: 2045–2047.CrossRefPubMed Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276: 2045–2047.CrossRefPubMed
28.
go back to reference Wang CD, Chan P. Clinicogenetics of Parkinson’s disease: a drawing but not completed picture. Neuroimmunol Neuroinflammation 2014, 1: 115–126.CrossRef Wang CD, Chan P. Clinicogenetics of Parkinson’s disease: a drawing but not completed picture. Neuroimmunol Neuroinflammation 2014, 1: 115–126.CrossRef
29.
go back to reference Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003, 33: 85–89.CrossRefPubMed Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003, 33: 85–89.CrossRefPubMed
30.
go back to reference Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2004, 351: 1972–1977.CrossRefPubMed Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 2004, 351: 1972–1977.CrossRefPubMed
31.
go back to reference Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010, 107: 378–383.CrossRefPubMed Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010, 107: 378–383.CrossRefPubMed
32.
go back to reference Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 2014, 46: 989–993.CrossRefPubMedPubMedCentral Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 2014, 46: 989–993.CrossRefPubMedPubMedCentral
34.
go back to reference Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 2016, 353. pii: aah3374. Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 2016, 353. pii: aah3374.
35.
go back to reference Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology 2017, 88: 1996–2002.CrossRefPubMedPubMedCentral Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology 2017, 88: 1996–2002.CrossRefPubMedPubMedCentral
36.
go back to reference Sheng JG, Delong Xu. Changes of striatal dopamine induced by MPTP in mice. Acta Universitatis Medicinalis Secondae Shanghai 1987, 7: 153–156. Sheng JG, Delong Xu. Changes of striatal dopamine induced by MPTP in mice. Acta Universitatis Medicinalis Secondae Shanghai 1987, 7: 153–156.
37.
go back to reference Le WD, Zhou XD, Jin GZ, Xu SX. Biochemical changes and rotaing behavior induced by MPTP injection in rat SNc. Chin Sci Bull 1988, 33: 786–789. Le WD, Zhou XD, Jin GZ, Xu SX. Biochemical changes and rotaing behavior induced by MPTP injection in rat SNc. Chin Sci Bull 1988, 33: 786–789.
38.
go back to reference Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005, 365: 595–597.CrossRefPubMed Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005, 365: 595–597.CrossRefPubMed
39.
go back to reference Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease. Hum Mol Genet 2006, 15: 1816–1825.CrossRefPubMed Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease. Hum Mol Genet 2006, 15: 1816–1825.CrossRefPubMed
Metadata
Title
Milestones of Parkinson’s Disease Research: 200 Years of History and Beyond
Authors
Song Li
Weidong Le
Publication date
01-10-2017
Publisher
Springer Singapore
Published in
Neuroscience Bulletin / Issue 5/2017
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-017-0178-2

Other articles of this Issue 5/2017

Neuroscience Bulletin 5/2017 Go to the issue